ArticleEmerging microbes & infections2016
Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
Article in Emerging microbes & infections, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Can human IgG subclasses distinguish between confirmed and unconfirmed SARS-CoV-2 infections?Journal, genetic engineering & biotechnology · 2024Article
- Time Course Evaluation of Enzyme-Linked Immunosorbent Assays Based on Cell-Free Recombinant Proteins for Detection of Antibodies against Middle East Respiratory Syndrome Coronavirus.Microbiology spectrum · 2022Article
- An Insight Into Detection Pathways/Biosensors of Highly Infectious Coronaviruses.Molecular biotechnology · 2022Review
- Evaluation of rapid antibody test and chest computed tomography results of COVID-19 patients: A retrospective study.Journal of medical virology · 2021Article
- Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study.Virologica Sinica · 2021Article
- Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.Nature reviews. Immunology · 2021Review
- The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.Frontiers in immunology · 2021Article
- Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World.Journal of clinical medicine · 2020Review
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.The New England journal of medicine · 2020Article
- Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?Pathogens (Basel, Switzerland) · 2020Review
- High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients.The Journal of infection · 2020Article
- Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient.The Journal of infection · 2020Article
- Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.Immunity · 2020Article
- Development and optimized pairing of mouse monoclonal antibodies for detecting hemagglutinin in novel H7 subtype influenza viruses.Science China. Life sciences · 2020Article
- Managing Preterm Infants Born to COVID-19 Mothers: Evidence from a Retrospective Cohort Study in Wuhan, China.Neonatology · 2020Article
- Evaluation of serological assays available in a biosafety level 2 laboratory and their application for survey of Middle East respiratory syndrome coronavirus among livestock in Ethiopia.The Journal of veterinary medical science · 2019Article
- A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals.Biosafety and health · 2019Article
- Development and validation of different indirect ELISAs for MERS-CoV serological testing.Journal of immunological methods · 2019Article
- A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry.Journal of virological methods · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first imported case of Middle East respiratory syndrome (MERS) in China recently occurred, allowing for the characterization of antibody titers in a series of the patient's sera using the following methods based on recombinant viral structural antigens: inactivated MERS coronavirus (MERS-CoV) enzyme-linked immunosorbent assay (ELISA), recombinant MERS-CoV spike (S, or fragments of S) ELISA, nucleoprotein (NP) ELISA and MERS S pseudovirus particle-based neutralization test (ppNT). A longitudinal profile of the infection showed that seroconversion detected by ELISAs based on the recombinant extracellular domain, S, S1 and receptor-binding domain (RBD) antigens occurred as early as neutralizing antibodies were detected by the ppNT and earlier than antibodies were detected by the inactivated MERS-CoV and N-terminal domain (NTD) ELISAs. Antibodies detected by the NP ELISA occurred last. Strong correlations were found between the S1, RBD and NP ELISAs and the inactivated MERS-CoV ELISA. The S and RBD ELISAs were highly correlated with the commercial S1 ELISA. The S ELISA strongly correlated with the ppNT, although the MERS-CoV, S1, NTD and RBD ELISAs were also significantly correlated with the ppNT (P<0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.